Official Title: “A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden”

This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

Study Type: Observational

Study Design: Cohort, Retrospective

Study Primary Completion Date: April 2008

Intervention(s) in this Clinical Trial

• Drug: Candesartan Cilexetil
  • oral once daily dose
• Drug: Losartan
  • once daily oral dose

Arms, Groups and Cohorts in this Clinical Trial

• : 1
  • Candesartan
• : 2
  • Losartan

Primary Measures

• Blood pressure recordings will be followed for the available observation periods with detail to when and to what degree levels less than 140/90 are reached.
  • Time Frame: 1999 - 2007
    Safety Issue?: No

Secondary Measures

• Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new
  • Time Frame: 1999 - 2007
    Safety Issue?: No
• Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward).
  • Time Frame: 1999 - 2007
    Safety Issue?: No

Inclusion Criteria:

• Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
• Diagnosed as hypertensive within 15 months

Exclusion Criteria:

• Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 -
• C09 inclusive

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 17 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Jan Stålhammar, MD Principal Investigator Eriksbergs vårdcentral  

Overall Contact: AstraZeneca Norway Study Information + 47 21 00 64 00 paal.hasvold@astrazeneca.com

Information obtained from ClinicalTrials.gov on August 28, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00620178

Study ID Number: NIS-CSE-ATA-2008/1

ClinicalTrials.gov Identifier: NCT00620178

Health Authority: Sweden: Regional Ethical Review Board